Insomnia is present in up to one third of the adult population worldwide, and it can present
independently or with other medical conditions such as mental, metabolic, or cardiovascular …

Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Abstract Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered
dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed …

Abstract Background and Objective Daridorexant is a dual orexin receptor antagonist for the
treatment of insomnia. In two phase III, 12-week studies in patients with insomnia disorder …

After a detailed description of orexins and their roles in sleep and other medical disorders,
we discuss here the current clinical evidence on the effects of dual (DORAs) or selective …

Daridorexant for the Treatment of Insomnia - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Preview …

Abstract Background and Objective The dual orexin receptor antagonist daridorexant,
studied in two phase III trials, dose-dependently improved objective and subjective sleep …

Daridorexant (Quviviq™) is a useful option for the treatment of insomnia disorder, which has
shown efficacy in younger and older adults. It antagonises the orexin receptors, thereby …

Background: Daridorexant is a novel dual orexin receptor antagonist that has shown efficacy
as a treatment for insomnia in multiple randomized clinical trials. However, the efficacy and …

Insomnia affects 4.4–4.8% of the world's population, but because the effect of hypnotic drugs
is limited and may cause harmful side-effects, scientists are turning their attention to …